Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Clin Cancer Res. 2018 Nov 29;25(6):1913–1922. doi: 10.1158/1078-0432.CCR-18-1176

Figure 4: CD3+ PD-1+ T cells from pooled glioma patient PBMCs produce higher levels of IFN-γ compared to the CD3+ PD-1 T cell population after T cell activation.

Figure 4:

A) The amount of IFN-γ produced in CD3+ PD-1, and CD3+ PD-1+ T cells from four glioma patient PBMCs 24 hours after CD3/CD28 activation. The dotted bar represents CD3+ PD-1 T cells that were not activated. The checkerboard bar represents CD3+ PD-1 T cells that were activated. The horizontal stripes bar represents CD3+ PD-1+ T cells that were activated. The results presented are a representative experiment that has been repeated multiple times with similar findings.

B) IFN-γ produced at 48hrs from the same set of cells as (A).

HHS Vulnerability Disclosure